XML 73 R43.htm IDEA: XBRL DOCUMENT v2.4.1.9
Goodwill and Other Intangibles (Tables)
 12 Months Ended
Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes in Goodwill by Operating Segment
The following table summarizes the changes in goodwill by operating segment for the years ended December 31, 2014 and 2013 (in thousands):
 
Performance Chemicals
 
Catalyst Solutions
 
Total
Balance at December 31, 2012
$
43,519

 
$
233,447

 
$
276,966

Foreign currency translation adjustments
84

 
7,153

 
7,237

Balance at December 31, 2013
43,603

 
240,600

 
284,203

Divestitures(a)
—

 
(15,088
)
 
(15,088
)
Foreign currency translation adjustments
(1,321
)
 
(24,532
)
 
(25,853
)
Balance at December 31, 2014
$
42,282

 
$
200,980

 
$
243,262



(a)
In 2014 we reduced Catalyst Solutions segment goodwill by $15.1 million in connection with the sale of our antioxidant, ibuprofen and propofol businesses and assets which closed on September 1, 2014. See Note 2 “Discontinued Operations” for additional information about this transaction.
Other Intangibles
Other intangibles consist of the following at December 31, 2014 and 2013 (in thousands):
 
Customer Lists and Relationships
 
Trade Names (a)
 
Patents and Technology
 
Land Use Rights
 
Manufacturing Contracts and Supply/Service Agreements
 
Other
 
Total
Gross Asset Value
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2012
$
85,167

 
$
26,943

 
$
47,876

 
$
6,203

 
$
8,523

 
$
23,412

 
$
198,124

Foreign currency translation adjustments and other
1,259

 
(36
)
 
867

 
173

 
(185
)
 
216

 
2,294

Balance at December 31, 2013
86,426

 
26,907

 
48,743

 
6,376

 
8,338

 
23,628

 
200,418

Acquisitions (b)
—

 
—

 
5,228

 
—

 
—

 
—

 
5,228

Divestitures (c)
(34,892
)
 
(8,171
)
 
(11,316
)
 
(4,929
)
 
(4,474
)
 
(4,758
)
 
(68,540
)
Foreign currency translation adjustments and other
(3,055
)
 
(1,181
)
 
(2,257
)
 
(40
)
 
—

 
(700
)
 
(7,233
)
Balance at December 31, 2014
$
48,479

 
$
17,555

 
$
40,398

 
$
1,407

 
$
3,864

 
$
18,170

 
$
129,873

Accumulated Amortization
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2012
$
(31,484
)
 
$
(8,486
)
 
$
(38,778
)
 
$
(1,079
)
 
$
(6,512
)
 
$
(17,321
)
 
$
(103,660
)
Amortization
(4,332
)
 
(995
)
 
(797
)
 
(166
)
 
(647
)
 
(1,129
)
 
(8,066
)
Foreign currency translation adjustments and other
(172
)
 
511

 
(779
)
 
(23
)
 
185

 
(211
)
 
(489
)
Balance at December 31, 2013
(35,988
)
 
(8,970
)
 
(40,354
)
 
(1,268
)
 
(6,974
)
 
(18,661
)
 
(112,215
)
Amortization
(2,839
)
 
(824
)
 
(388
)
 
(42
)
 
(368
)
 
(1,276
)
 
(5,737
)
Divestitures (c)
14,487

 
1,539

 
5,738

 
(100
)
 
4,164

 
1,756

 
27,584

Foreign currency translation adjustments and other
1,409

 
343

 
2,173

 
3

 
—

 
692

 
4,620

Balance at December 31, 2014
$
(22,931
)
 
$
(7,912
)
 
$
(32,831
)
 
$
(1,407
)
 
$
(3,178
)
 
$
(17,489
)
 
$
(85,748
)
Net Book Value at December 31, 2013
$
50,438

 
$
17,937

 
$
8,389

 
$
5,108

 
$
1,364

 
$
4,967

 
$
88,203

Net Book Value at December 31, 2014
$
25,548

 
$
9,643

 
$
7,567

 
$
—

 
$
686

 
$
681

 
$
44,125



(a)
Trade names include a gross carrying amount of $9.2 million for an indefinite-lived intangible asset.
(b)
Increase in Patents and Technology relates to a purchase accounting adjustment in connection with our acquisition of Cambridge Chemical Company, Ltd.
(c)
In 2014 we reduced intangible assets by $68.5 million and related accumulated amortization by $27.6 million in connection with the sale of our antioxidant, ibuprofen and propofol businesses and assets which closed on September 1, 2014. See Note 2 “Discontinued Operations” for additional information about this transaction.
Total Estimated Amortization Expense of Other Intangibles for Next Five Fiscal Years
Total estimated amortization expense of other intangibles for the next five fiscal years is as follows (in thousands):
 
Estimated Amortization Expense
2015
$
3,482

2016
$
3,050

2017
$
2,858

2018
$
2,682

2019
$
2,567